Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
XRF ScientificASX:XRF -0.53%94 Cash-to-Debt is 4.05 as of Jun. 2026, which is 48% above its 10-year median of 2.73. GuruFocus rates ASX:XRF with a GF Score™ of 94/100 and a GF Value™ of A$1.79 (Fairly Valued). The stock has 1 warning sign investors should review. Among 543 Conglomerates companies, XRF Scientific ranks better than 81.58% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. XRF Scientific's cash to debt ratio for the quarter that ended in Jun. 2026 was 4.05.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, XRF Scientificcould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for XRF Scientific's Cash-to-Debt or its related term are showing as below:
ASX:XRF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.21 Med: 2.73 Max: 4.26
Current: 4.05
During the past 13 years, XRF Scientific's highest Cash to Debt Ratio was 4.26. The lowest was 0.21. And the median was 2.73.
ASX:XRF's Cash-to-Debt is ranked better than 81.58% of 543
companies
in the Conglomerates industry
Industry Median: 0.45
vs ASX:XRF: 4.05
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
XRF Scientific Cash-to-Debt Related Terms
XRF Scientific Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for XRF Scientific's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Conglomerates subindustry, XRF Scientific's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XRF Scientific Cash-to-Debt vs Conglomerates Industry
For the Conglomerates industry and Industrials sector, XRF Scientific's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where XRF Scientific's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XRF Scientific (ASX:XRF) has a Cash-to-Debt of 4.05 as of Jun. 2026. This is 48% above median its historical median of 2.73. Over the past decade, XRF Scientific's Cash-to-Debt has ranged from 0.21 to 4.26. According to the industry distribution chart, XRF Scientific ranks #100 out of 543 companies in the Conglomerates industry, placing it in the top 18.4%.
Is XRF Scientific's Cash-to-Debt too high?
XRF Scientific's current Cash-to-Debt of 4.05 is 48% above median its 10-year median of 2.73. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 4.26. The Conglomerates industry median Cash-to-Debt is 0.45. XRF Scientific's value of 4.05 is 800% above this industry median. Based on the distribution chart, XRF Scientific ranks #100 out of 543 companies in the Conglomerates industry, which is in the top quartile — a strong position relative to peers. Overall, XRF Scientific has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does XRF Scientific's Cash-to-Debt compare to MMM and HON?
According to the Conglomerates industry distribution chart, XRF Scientific ranks #100 out of 543 companies for Cash-to-Debt. This places XRF Scientific in the top 18% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 0.45. XRF Scientific's value of 4.05 is 800% above this benchmark. Historically, XRF Scientific's own Cash-to-Debt has ranged from 0.21 to 4.26 over the past decade. While the company's 10-year median is 2.73 vs. the industry median of 0.45, XRF Scientific has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Conglomerates company?
The median Cash-to-Debt among Conglomerates companies is 0.45, based on 543 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. XRF Scientific's current Cash-to-Debt of 4.05 is 800% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Conglomerates industry, the median Cash-to-Debt is 0.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. XRF Scientific's current Cash-to-Debt is 4.05, which is 48% above median its own 10-year median of 2.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XRF Scientific stock overvalued right now?
Based on GuruFocus' analysis, XRF Scientific (ASX:XRF) is currently considered Fairly Valued. The stock's GF Value™ is A$1.79, compared to a current price of A$1.88 — trading 4.7% above its estimated fair value. The current Cash-to-Debt is 4.05, which is 48% above median its 10-year median of 2.73 and 800% above the Conglomerates industry median of 0.45. XRF Scientific's overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For XRF Scientific (ASX:XRF), the current Cash-to-Debt is 4.05 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is XRF Scientific (ASX:XRF) Overvalued in 2026?
Based on GuruFocus' analysis, XRF Scientific stock appears to be overvalued.
The current stock price of A$1.88 is trading 4.7% above its estimated GF Value™ of A$1.79.
GuruFocus considers XRF Scientific to be Fairly Valued.
Key valuation signals for ASX:XRF:
Cash-to-Debt: 4.05 (48% above median its 10-year median of 2.73)
GF Value™: A$1.79 vs. price of A$1.88 (4.7% above fair value)
Industry Position: 800% above the Conglomerates median (#100 of 543)
No single metric tells the full story. See the ASX:XRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
XRF Scientific Ltd is engaged in the business of manufacturing and marketing precious metal products, specialized chemicals and instruments for the scientific, analytical and mining industries. It operates through the following segments: Capital Equipment, Precious Metals, and Consumables. The company generates maximum revenue from the Capital Equipment segment that Manufactures sample preparation products and analytical instruments. Geographically, it derives a majority of revenue from Australia and also has a presence in Canada and Europe. Some of its product includes Electric Fusion Machines; Fusion Flux; Crushing and Pulverising, platinum lab ware and others.
94GF Score
Get the complete analysis for ASX:XRF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:XRF has been successfully added to your 
